

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
27 January 2005 (27.01.2005)

PCT

(10) International Publication Number  
**WO 2005/007603 A3**

(51) International Patent Classification<sup>7</sup>: **C07C 43/205**,  
205/37, 217/84, C07F 9/09, A61K 31/09, 31/136, 31/661,  
A61P 35/00

(IT). MARCELLINI, Marcella [IT/IT]; c/o Simgma-Tau  
Industrie Farmaceutiche Riunite S.p. .A., Via Pontina, Km.  
30,400, I-00040 Pomezia (IT).

(21) International Application Number:  
PCT/IT2004/000375

(74) Agents: SPADARO, Marco et al.; Cavattoni - Raimondi,  
Viale dei Parioli, 160, I-00197 Roma (IT).

(22) International Filing Date: 6 July 2004 (06.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0316910.9 18 July 2003 (18.07.2003) GB

(71) Applicant (for all designated States except US):  
SIGMA-TAU INDUSTRIE FARMACEUTICHE  
RIUNITE S.p.A. [IT/IT]; Viale Shakespeare, 47, I-00144  
Roma (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GIANNINI,  
Giuseppe [IT/IT]; c/o Simgma-Tau Industrie Farmaceu-  
tiche Riunite S.p. .A., Via Pontina, Km. 30,400, I-00040  
Pomezia (IT). MARZI, Mauro [IT/IT]; c/o Simgma-Tau  
Industrie Farmaceutiche Riunite S.p. .A., Via Pontina, Km.  
30,400, I-00040 Pomezia (IT). ALLOATTI, Domenico  
[IT/IT]; c/o Simgma-Tau Industrie Farmaceutiche Riunite  
S.p. .A., Via Pontina, Km. 30,400, I-00040 Pomezia  
(IT). TINTI, Maria, Ornella [IT/IT]; c/o Simgma-Tau  
Industrie Farmaceutiche Riunite S.p. .A., Via Pontina,  
Km. 30,400, I-00040 Pomezia (IT). RICCIONI, Teresa  
[IT/IT]; c/o Simgma-Tau Industrie Farmaceutiche Riunite  
S.p. .A., Via Pontina, Km. 30,400, I-00040 Pomezia

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).


**Published:**

— with international search report

(88) Date of publication of the international search report:  
7 July 2005

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: FLUOROCOMBRETASTATIN AND DERIVATIVES THEREOF



(I)

(57) Abstract: The present invention is related to new  
derivatives of Combretastatin, of Formula (I) obtained  
by total synthesis. The strategy developed for each of the  
compounds is to i) replace a halogen (i.e. fluorine atom)  
to hydrogen on olefinic bond; ii) replace an aromatic  
ring in a natural product with an amino-aromatic ring.  
Said compounds recognize and bind the tubulin site: are  
useful for treating pathological states which arise from or  
are exacerbated by cell proliferation - as anticancer and/or  
antiangiogenic activity, in a mammal - to pharmaceutical  
compositions comprising these compounds.

WO 2005/007603 A3